Veru stock tumbles after pricing public offering at $3 per share By Investing.com
Update: 2025-10-30
Description
Veru Incorporated's stock plummeted by 20% following a public offering to raise $25.2 million. The biopharmaceutical company plans to sell 1.4 million shares and offer pre-funded warrants for up to 7 million more. The funds will primarily go towards the Phase 2B PLATEAU clinical study for their lead drug, enobosarm, and general business needs. While the offering may dilute current shareholders, Veru could potentially raise an additional $50.4 million if all warrants are exercised. The offering is managed by Canaccord Genuity and Oppenheimer, with a projected close date of October 31, 2025. The market's reaction and enobosarm's clinical trial progress will determine Veru's future in the competitive pharmaceutical world.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
